MedTrace Logo

Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects

NCT00148382 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2007-04-11

No results posted yet for this study

Summary

The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese

Conditions

Interventions

DRUG

ATL-962

Sponsors & Collaborators

  • Alizyme

    lead INDUSTRY

Principal Investigators

  • Lawrence Galitz · SFBCI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-04-30
Completion
2005-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148382 on ClinicalTrials.gov